What changed in Bristol-Myers Squibb Company's latest annual report
In the year ended 31 Dec 2025, Bristol-Myers Squibb Company's revenue fell 0.2% to USD 48.19bn, from USD 48.30bn; shareholders' equity rose 13.1% to USD 18.47bn, from USD 16.34bn; long-term debt fell 10% to USD 42.85bn, from USD 47.60bn.
Year ended 31 Dec 2025. Source: 10-K filed 11 Feb 2026, read it on SEC EDGAR.
USD 48.30bn to USD 48.19bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 48.30bn | 48.19bn | Down 0.2% |
| Net income | -8.95bn | 7.05bn | Not comparable |
| Total assets | 92.60bn | 90.04bn | Down 2.8% |
| Total liabilities | 76.22bn | 71.53bn | Down 6.1% |
| Long-term debt | 47.60bn | 42.85bn | Down 10% |
| Cash and cash equivalents | 10.35bn | 10.21bn | Down 1.3% |
| Shareholders' equity | 16.34bn | 18.47bn | Up 13.1% |
Questions people ask
Did Bristol-Myers Squibb Company's revenue grow last year?
Revenue fell 0.2%, from USD 48.30bn to USD 48.19bn in the year ended 31 Dec 2025.
Is Bristol-Myers Squibb Company profitable?
Yes. Net income was USD 7.05bn in the year ended 31 Dec 2025. The year before: a net loss of USD 8.95bn.
How much cash and debt does Bristol-Myers Squibb Company have?
At its latest year end (31 Dec 2025), Bristol-Myers Squibb Company reported cash and cash equivalents of USD 10.21bn and long-term debt of USD 42.85bn.
Where do these numbers come from?
From Bristol-Myers Squibb Company's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Bristol-Myers Squibb Company?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Regeneron Pharmaceuticals, Inc.Cash and cash equivalents up 25.3%